Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer

Kawana, Youko; Komiya, Akira; Ueda, Takeshi; Nihei, Naoki; Kuramochi, Hiroaki; Suzuki, Hiroyoshi; Yatani, Ryuichi; Imai, Takashi; Dong, Jin‐Tang; Imai, Toshio; Yoshie, Osamu; Barrett, J. Carl; Isaacs, John T.; Shimazaki, Jun; Itô, Haruo; Ichikawa, Tomohiko

doi:10.1002/(sici)1097-0045(19970801)32:3<205::aid-pros7>3.0.co;2-j

Cited by 64 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, we have localized ELF5 to human chromosome 11p13 ± 15, a region which undergoes loss of heterozygosity (LOH) in many types of cancer, such as ductal breast carcinoma (Lichy et al, 1998), lung carcinoma (Iizuka et al, 1995), rhabdoid tumor of the kidney (Hirose et al, 1996), prostate carcinoma (Kawana et al, 1997;Dahiya et al, 1997), gastric carcinoma (Ba a et al, 1996), and ovarian carcinoma . This region is believed to harbor several tumor suppressor genes (Ba a et al, 1996;Coleman et al, 1997;Feinberg, 1996;Gao et al, 1997;Ichikawa et al, 1996;Iizuka et al, 1995;Zenklusen et al, 1995), based upon both LOH data and the ability to inhibit the tumorigenicity in chemically induced murine squamous cell carcinomas upon introduction of human chromosome 11 (Zenklusen et al, 1995).…”

Section: Discussionmentioning

confidence: 99%

“…The markers most tightly linked to ELF5 are D11S3990 (6.5cR) and D11S3998 (15.9cR) (lod score43.0), and these markers are located in the region of 11p13 ± 15 (Figure 3). This chromosomal region frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma (Ba a et al, 1996;Dahiya et al, 1997;Hirose et al, 1996;Iizuka et al, 1995;Kawana et al, 1997;Lichy et al, 1998;Wilson et al, 1996).…”

Section: Comparison Of Human and Mouse Elf5 Amino Acid Sequencesmentioning

confidence: 99%

See 1 more Smart Citation

A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines

Zhou

Tymms

et al. 1998

Oncogene

View full text Add to dashboard Cite

The ETS transcription factors are a large family implicated in the control of cellular proliferation and tumorigenesis. In addition, chromosomal translocations involving ETS family members are associated with a range of di erent human cancers. Given the extensive involvement of ETS factors in tumorigenesis, it becomes important to identify any additional ETS genes that may also play oncogenic roles. We identify a novel gene, ELF5, that appears to belong to the ELF (E74-likefactor) subfamily of the ETS transcription factor family, based upon similarity within the`ETS domain'. ELF5 displays a similar, but more restricted, expression pattern to that of the newly isolated epithelium-speci®c ETS gene, ELF3. Unlike most other ETS family members, ELF5 is not expressed in hematopoietic compartments, but is restricted to organs such as lung, stomach, kidney, prostate, bladder and mammary gland. ELF5 is localized to human chromosome 11p13 ± 15, a region that frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma, including those of breast, kidney and prostate. We ®nd that ELF5 expression is not detectable in a number of carcinoma cell lines, some of which display loss or rearrangement of an ELF5 allele. Similar to other ETS family members, ELF5 displays speci®c binding to DNA sequences containing a GGAA-core. In addition, ELF5 is able to transactivate through these ETS sequences, present upstream from a minimal promoter. Our data suggest that ELF5 may play roles in mammary, lung, prostate and/or kidney function, and possibly also in tumorigenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Comparison Of Human and Mouse Elf5 Amino Acid Sequencesmentioning

confidence: 99%

A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines

Zhou

Tymms

et al. 1998

Oncogene

View full text Add to dashboard Cite

show abstract

“…[4][5][6] We have investigated several regions of chromosomal loss in prostate cancer using LOH analysis. [7][8][9][10][11][12][13][14][15] CGH is a molecular technique that allows screening of the whole genome for DNA sequence copy number alterations. Regions of increased copy number may contain oncogenes, whereas regions of decreased copy number may contain putative TSGs.…”

Section: Introductionmentioning

confidence: 99%

Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization

Fukasawa

Kino

Kobayashi

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate-specific antigen (PSA) screening has led to a remarkable increase in prostate cancer cases undergoing operative therapy. Over half of patients with locally advanced cancer (^pT3) develop rising PSA levels (biochemical failure) within 10 years. It is very difficult to predict which patients will progress rapidly to advanced disease following biochemical failure (BF). Therefore, a more useful prognostic factor is needed to suggest the most appropriate therapies for each patient. To determine chromosomal aberrations, we examined 30 patients with stage pT2 or pT3 primary prostate adenocarcinomas and no metastases (pN0M0) by comparative genomic hybridization (CGH). Laser capture microdissection (LCM) was used to gather cancer cells from frozen prostate specimens. Common chromosomal alterations included losses on 2q23-24, 4q26-28, 6q14-22, 8p12-22 and 13q21-31, as well as gains on 1p32-36, 6p21 and 17q21-22. Losses at 8p12-22 and 13q21-31 were observed more frequently in pT3 than pT2 tumors (Po0.05 and Po0.01, respectively). Losses at 8p12-22 were more frequent in tumors with BF (Po0.05), and those at 13q12-21 were more frequent in tumors with Gleason score (GS) 7 or more than lower GS (Po0.05). These findings suggest that losses of 8p12-22 and 13q21-31 are important determinants of prostate cancer progression.

show abstract

“…N, normal tissues; P, primary site; LN, lymph node metastasis; B, bone metastasis; Li, liver metastasis. Lsm1 expression in prostate cancer S Takahashi et al while frequent in Japanese (Kawana et al, 1997). The standard form of CD44 is also a candidate metastasis suppressor gene located on chromosome 11p13, with potential involvement in prostate cancer progression through decreased expression (Gao et al, 1997).…”

Section: Discussionmentioning

confidence: 99%

Down-regulation of Lsm1 is involved in human prostate cancer progression

et al. 2002

View full text Add to dashboard Cite

Elucidation of genetic alterations is an approach to understanding the underlying molecular mechanisms of progression of human prostate cancers. We have searched for genes differentially expressed in advanced prostate cancers using cDNArepresentational difference analysis, and thereby isolated the Lsm1 as one of down-regulated gene. An Lsm1 expression vector was transfected into PC3 cells, normally featuring down-regulated Lsm1, and four transfectants were established. No differences in morphology or cell proliferation were evident in comparison with parent PC3 or PC3/mock-transfectants. In contrast, significant suppression of invasive potential or metastatic ability of Lsm1 transfectants was observed in the Matrigel chemoinvasion assay and in nude mice, respectively. With human prostate cancers, almost all of informative prostatectomised cases without neoadjuvant therapy showed allelic retention in the Lsm1 region, whereas refractory cancers frequently showed allelic loss in this region. No critical gene mutations were found in open reading frame of Lsm1 in prostate cancers examined by PCR -SSCP analysis, including localised and refractory cancers. These results suggest that Lsm1 is deeply involved in prostate cancer progression through its down-regulation, independent of any gene mutation.

show abstract

Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer

Cited by 64 publications

References 22 publications

A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines

A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines

Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization

Down-regulation of Lsm1 is involved in human prostate cancer progression

Contact Info

Product

Resources

About